Facebook post by University of Helsinki

The majority of patients fail to respond to immunotherapies because targetable tumour characteristics vary from patient to patient. Therapies that target tumour-specific antigens (so-called neoantigens) invoke a strong and specific anti-tumour immune response. However, a greater degree of personalisation is required.
Neoantigens: key to more effective, personalised anti-cancer immunotherapy helsinki.fi

Professor Cerullo explores the business opportunities of PeptiCHIP, a microfluidic device for neoantigen purification for immunotherapy.